# Supra NA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/supra-na

- Industry: Biotechnology
- Headquarters: Tianjin, China
- Latest round: Series A (Oct 15, 2025)
- Investors on record: 1

## About

Founded in 2021 and headquartered in Tianjin, China, Tianjin Supra Nucleic Acid Technology Co., Ltd., operating as Supra NA, specializes in the R&D of nucleic acid smart materials and nanotechnology applications. The company aims to build a full-chain capability from fundamental research to industrialization in the emerging field of synthetic biology. In October 2025, the firm closed a series A funding round.

The company focuses on the development of DNA-based intelligent materials and nanodevices. Its research areas include supramolecular structure assembly, nanomaterial preparation and applied studies related to nucleic acid-based nanotechnologies for biomedical and diagnostic purposes.

The company generates revenue through R&D services and collaborations with partners in the biomedical and nanotechnology sectors.

Supra NA plans to use the series A funding to strengthen research capabilities, expand its technical team and accelerate the development of its core product pipeline for broader biomedical applications.

## Funding rounds

- Series A, Oct 15, 2025 — Trinity Innovation Fund

## Investors

- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series A